From: Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
Adverse Event
n/patient-years of exposure (Incidence Rate per 100 Patient-years†)
Sitagliptin
100 mg
Non-exposed
Difference between Sitagliptin and
Non-exposed (95% CI)*
Any malignancy
46/4690 (1.0)
40/3930 (1.0)
-0.0 (-0.5, 0.4)